The reason for choosing visfatin as a biomarker in periodontitis diseases is that less studies have been done on it, in terms of cost, invasiveness and the method of measurement, it has priority over other inflammatory biomarkers, and in addition, it is a newer biomarker that needs more studies. Here, NAMPT is linked to periodontitis.